Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 16/20 | 0.64 |
| ▸ | HCK | P08631 | 6/20 | 0.64 |
| ▸ | TNF | P01375 | 2/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.64 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 3/20 | 0.58 |
| ▸ | BRAF | P15056 | 3/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593428 | 0.85 | MAPK14 (0.69) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL295357 | 0.85 | MAPK14 (0.69) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL296301 | 0.82 | MAPK14 (0.73) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL6298539 | 0.81 | MAPK14 (0.76) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL296302 | 0.81 | MAPK14 (0.64) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL296828 | 0.81 | MAPK14 (0.64) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL296829 | 0.81 | MAPK14 (0.64) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL29594890 | 0.81 | MAPK14 (0.64) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL29594163 | 0.81 | MAPK14 (0.77) | MAPK14MAPK12HCKTNFMAPK13 | |
| SCHEMBL295665 | 0.81 | MAPK14 (0.77) | MAPK14MAPK12HCKTNFMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050163726-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050163726-A1 | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors | CHRM3, CHRNB1, CHRM2 | MAPK14 83/4885MAPK12 75/4885HCK 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.